Ghaziabad Online

Eosinophilic Esophagitis Market: Industry Analysis, Drugs, Key Companies by DelveInsight | Takeda, Sanofi, Regeneron Pharmaceuticals, Bristol-Myers Squibb, AstraZeneca and Others

 Breaking News
  • No posts were found

Eosinophilic Esophagitis Market: Industry Analysis, Drugs, Key Companies by DelveInsight | Takeda, Sanofi, Regeneron Pharmaceuticals, Bristol-Myers Squibb, AstraZeneca and Others

May 20
02:36 2021
Eosinophilic Esophagitis Market: Industry Analysis, Drugs, Key Companies by DelveInsight | Takeda, Sanofi, Regeneron Pharmaceuticals, Bristol-Myers Squibb, AstraZeneca and Others

Eosinophilic Esophagitis Market

DelveInsight’s Eosinophilic Esophagitis (EoE) Market report provides a thorough comprehension of the Eosinophilic Esophagitis, historical and forecasted epidemiology, and the Eosinophilic Esophagitis market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Eosinophilic Esophagitis market report also proffers an analysis of the current Eosinophilic Esophagitis treatment algorithm/practice, market drivers, market barriers, and unmet medical needs. 

 

Some of the imperative takeaways of the Eosinophilic Esophagitis Market Research Report:

  • A slew of companies such as EsoCap AG, Arena Pharmaceutical, GlaxoSmithKline, Dr Falk Pharma GmbH, Takeda, Regeneron Pharmaceuticals, Sanofi, Bristol-Myers Squibb, Ellodi Pharmaceuticals, AstraZeneca, Allakos, and others are developing therapies to influence Eosinophilic Esophagitis treatment outlook. 
  • Increased understanding of the clinical manifestations of the disease in conjunction with improved diagnosis and evolving treatment landscape will boost the Eosinophilic Esophagitis market landscape scenario.. 
  • The US FDA has granted priority review, breakthrough therapy designation, and orphan designation to Budesonide Oral Suspension (BOS) for the EoE treatment. 
  • In the Phase II study, RPC4046 demonstrated positive results. Currently, Bristol-Myers Squibb is conducting a Phase III clinical study to evaluate the efficacy and safety of CC-93538 in adult and adolescent participants with the indication.
  • APT-1011 has received orphan drug designation from the FDA. It is currently in Phase III development (FLUTE II), following the successful completion of its phase II study (FLUTE I) in 2019. 
  • Benralizumab is currently approved under the brand name Fasenra as an add-on maintenance treatment of severe asthma in patients aged ≥12 years and with an eosinophilic phenotype. Now, it is being evaluated in the Phase III study for the treatment of EoE. 
  • Currently, Lirentelimab is being evaluated in Phase II/III study for the Eosinophilic Esophagitis treatment in adult and adolescent subjects. The US FDA has granted orphan drug designation to antolimab for the treatment of EoE. 

 

Get a sample copy of this report: Eosinophilic Esophagitis Market Size Landscape

 

Eosinophilic Esophagitis (EoE) represents a chronic, local immune-mediated oesophagal disease, characterized clinically by symptoms related to oesophagal dysfunction and histologically by eosinophil-predominant inflammation. 

As per the estimates by DelveInsight, the total diagnosed Eosinophilic Esophagitis prevalent cases in 2020 were 547,924 cases. The highest prevalent cases were observed in the United States, accounting for approximately 58% of the total cases. 

 

Eosinophilic Esophagitis Treatment Market 

The Eosinophilic Esophagitis treatment involves Drugs, Diet, and Dilation. The first two components, which involve the use of proton pump inhibitors (PPIs), corticosteroids, immunosuppressant’s, and empirical diets or guided food elimination based on allergy tests, are more useful in the initial phases. In contrast, endoscopic dilation is reserved for oesophagal strictures. 

Three dietary approaches for the management of EoE have emerged: the elemental diet, empiric dietary restrictions, and targeted dietary restrictions based on allergy testing.

PPIs are helpful as a first-line treatment for EoE patients. This therapy reduces acid production in the stomach and can reduce oesophagal inflammation. PPIs are recommended to be administered twice daily and continued for a minimum 2-month course after oesophagal eosinophilia is discovered. Afterwards, a repeat endoscopy with biopsies is performed to assess for persistent eosinophilic infiltration.

 

Eosinophilic Esophagitis Emerging Therapies Along with Key Players

  • Budesonide Oral Suspension: Takeda
  • Dupilumab: Regeneron Pharmaceuticals/Sanofi
  • Cendakimab: Bristol-Myers Squibb
  • APT-1011: Ellodi Pharmaceuticals
  • Benralizumab: AstraZeneca
  • Lirentelimab: Allakos 
  • And several others.

 

Final thoughts on Eosinophilic Esophagitis Market Growth 

 

Eosinophilic Esophagitis Market Drivers such as increasing awareness, the emergence of non-invasive modalities, identification of biomarkers, development of animal models are responsible for Market Growth. In contrast, Eosinophilic Esophagitis Market Barriers such as high cost of treatment, lack of multidisciplinary management, and lack of optimal endpoint for treatment will nosedive the market size. 

 

Request for a Webex demo of the report @ Eosinophilic Esophagitis Treatment Market Size

 

Table of Contents

 

1

Eosinophilic Esophagitis (EoE) Key Insights 

2

Eosinophilic Esophagitis Report Introduction

3

Eosinophilic Esophagitis Market Overview at a Glance

4

Eosinophilic Esophagitis Patient Split at a Glance

5

Executive Summary of Eosinophilic Esophagitis 

6

Eosinophilic Esophagitis Disease Background and Overview

7

EoE Treatment

8

Guidelines for Management of EoE 

9

Eosinophilic Esophagitis Epidemiology and Patient Population 

9.1

The United States

9.2

EU5 Countries

9.2.1

Germany

9.2.2

France

9.2.3

Italy

9.2.4

Spain

9.2.5

The United Kingdom

9.3

Japan

10

Organizations contributing toward the fight against EoE

11

EoE Patient Journey

12

Case Report

13

Eosinophilic Esophagitis Marketed Drug

13.1

Jorveza: Dr Falk Pharma GmbH

14

Eosinophilic Esophagitis Emerging Drugs

14.1

Budesonide Oral Suspension: Takeda

14.2

Dupilumab: Regeneron Pharmaceuticals/Sanofi

14.3

Cendakimab: Bristol-Myers Squibb

14.4

APT-1011: Ellodi Pharmaceuticals

14.5

Benralizumab: AstraZeneca

14.6

Lirentelimab: Allakos

15

Other Promising Therapies

15.1

ESO-101: EsoCap AG

15.2

Etrasimod: Arena Pharmaceutical

15.3

Mepolizumab: GlaxoSmithKline

16

7MM Eosinophilic Esophagitis Market Analysis

16.1

The United States Eosinophilic Esophagitis Market Size

16.2

EU-5 Eosinophilic Esophagitis Market Size

16.2.1

Germany Market Size

16.2.2

France Market Size

16.2.3

Italy Market Size

16.2.4

Spain Market Size

16.2.5

The United Kingdom Market Size

16.3

Japan Eosinophilic Esophagitis Market Size

17

KOL Views

18

Eosinophilic Esophagitis Market Drivers

19

Eosinophilic Esophagitis Market Barriers

20

SWOT Analysis of Eosinophilic Esophagitis

21

Eosinophilic Esophagitis Unmet Needs

22

Appendix

23

DelveInsight Capabilities

24

Disclaimer

25

About DelveInsight

 

Browse full report with detailed TOC with charts, figures, tables @ Eosinophilic Esophagitis Market Share Report

 

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/eosinophilic-esophagitis-market


Warning: count(): Parameter must be an array or an object that implements Countable in /home/ghaziabadonline/public_html/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share